Dept. of Economics
Mail Stop 021
P.O. Box 9110
Waltham, MA 02454
Information about this author at RePEc
NBER Working Papers and Publications
|May 2009||Toxic Exposure in America: Estimating Fetal and Infant Health Outcomes|
with Nikhil Agarwal, Chanont Banternghansa: w14977
We examine the effect of exposure to toxic releases that are tracked by the Toxic Release Inventory (TRI) on county-level infant and fetal mortality rates in the United States between 1989-2002. We find significant adverse effects of TRI concentrations on infant mortality rates, but not on fetal mortality rates. In particular, we estimate that the average county-level decrease in aggregate TRI concentrations saved in excess of 25,000 infant lives from 1989-2002. Using a value of life of $1.8M - $8.7M, the savings in lives would be valued at $45B - $217.5B. We also find that the effect of toxic exposure on health outcomes varies across pollution media: air pollution has a larger impact on health outcomes than either water or land. And, within air pollution, releases of carcinogens are parti...
Published: Toxic Exposure in America: Estimating Fetal and Infant Health Outcomes From 14 Years of TRI Reporting with Chanont Banternghansa and Linda Bui Journal of Health Economics, July 2010
|January 1996||The Roles of Marketing, Product Quality, and Price Competition in the Growth and Composition of the U.S. Antiulcer Drug Industry|
with Ernst R. Berndt, David H. Lucking-Reiley, Glen L. Urban
in The Economics of New Goods, Timothy F. Bresnahan and Robert J. Gordon, editors
|October 1994||The Roles of Marketing, Product Quality and Price Competition in the Growth and Composition of the U.S. Anti-Ulcer Drug Industry|
with Ernst R. Berndt, David Reiley, Glen Urban: w4904
The introduction of Tagamet in the United States in 1977 represented both a revolution in ulcer therapy and the beginning of an important new industry. Today there are four prescription H2- antagonist drugs: Tagamet, Zantac, Pepcid and Axid, and they comprise a multi-billion dollar market for the treatment of ulcers and other gastric acid conditions. In this paper, we examine the determinants of sales in this market, using a carefully constructed data set made possible by IMS America. We concentrate particularly on the marketing of these drugs to physicians through detailing and medical journal advertising, and we make an innovative attempt to distinguish between 'industry-expanding' and 'rivalrous' marketing efforts. We find that the impact of total marketing on the expansion of overa...
- Berndt, Ernst R., Linda T. Bui, David R. Reiley and Glen L. Urban. "Information, Marketing, And Pricing In The U.S. Antiulcer Drug Market," American Economic Review, 1995, v85(2), 100-105.
- The Economics of New Goods, Timothy Bresnahan and Robert Gordon, eds. pp. 277, (Chicago: University of Chicago Press, 1997).